Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...
Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...
Lexicon收到了FDA對Zynquista的完整回覆信；表示這一預期的溝通符合之前披露的戰略決定，即停止Zynquista的上市準備，並專注於其臨牀開發...
Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development Pipeline
Lexicon收到了關於Zynquista的完整回覆函；表示這封來自FDA的預期通信與之前披露的戰略決策一致，即停止Zynquista的上市準備，專注於其臨牀開發管道。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。